Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence
Authors' conclusion
Catheter-based radiofrequency RDN can be a cost-effective strategy for uncontrolled hypertension in the UK, with an ICER substantially below the NICE cost-effectiveness threshold.
Study context
- Population
- Patients with uncontrolled hypertension, UKmodel
- Comparison
- RF RDN vs sham control
- Outcome
- ICER (cost per QALY gained) vs NICE threshold of £20 000-30 000 per QALY gained
- Follow-up
- Lifetime
Methodological detailsdecision-analytic model, lifetime horizon, UK NHS perspective, scenario and sensitivity analyses, Base case effect size from SPYRAL HTN-ON MED trial; costs from NHS England data
- Decision-analytic model
- Lifetime horizon
- UK NHS perspective
- Scenario and sensitivity analyses
- Base case effect size from SPYRAL HTN-ON MED trial; costs from NHS England data
Main finding
As reported in the abstract
Lifetime cost-effectiveness
Quality-adjusted life years (QALYs) added
0.35
Incremental cost
£4763
Incremental cost-effectiveness ratio (ICER) per QALY gained
£13 482
Further findings
Relative risk of clinical events · 10 years
- Stroke
- 0.80
- Myocardial infarction (MI)
- 0.88
- Heart failure (HF)
- 0.72
Original publication
Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence. Eur Heart J Qual Care Clin Outcomes. Published 9 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →